The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: A study based on therapeutic drug monitoring data

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 787-790

  Hendset, Magnhild ^a   Molden, Espen ^a,b   Enoksen, Torill Bakko ^b   Refsum, Helge ^a   Hermann, Monica ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

aripiprazole; CYP2D6; drug interaction; duloxetine; risperidone

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; DULOXETINE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; MALE; MENTAL PATIENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 78649349920     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181fc50d5     Document Type: Article

References (24)

1. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol. 2009;24:177-190.
2. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23:523-541.
3. Basu M, Duckett J. The treatment of urinary incontinence with duloxetine. J Obstet Gynaecol. 2008;28:166-169.
4. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009; CD007115.
5. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
6. Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27:28-34.
7. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-177.
8. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36:2484-2491.
9. Huang ML, Van PA, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268.
10. Swainston HT, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736.
11. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005; 20:55-64.
12. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29:1263-1268.
13. Van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl). 1994;114:53-62.
14. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151.
15. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically releVant pharma-cokinetic drug interaction. J Clin Psychopharmacol. 2002;22:419-423.
16. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227.
17. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233-238.
18. Kirschbaum KM, Muller MJ, MaleVani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9:212-218.
19. Cytochrome P450 Drug Interaction table. Available at: http://medicine. iupui.edu/clinpharm/ddis/table.asp. Accessed June 18, 2010.
20. Hendset M, Molden E, Refsum H, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisper-idone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009;29:537-541.
21. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripi-prazole. Eur J Clin Pharmacol. 2007;63:1147-1151.
22. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28:744-749.
23. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 2007;40:107-110.
24. De LJ, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.